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OBJECTIVES We evaluated the long-term influence of intramural delivery of advanced c-myc neutrally
charged antisense oligonucleotides (Resten-NG) on neointimal hyperplasia after stenting in
a pig model.
BACKGROUND Neointimal hyperplasia after percutaneous coronary interventions is one of the key compo-
nents of the restenotic process. The c-myc is a critical cell division cycle protein involved in
the formation of neointima.
METHODS In short-term experiments, different doses (from 500 g to 5 mg) of Resten-NG or saline
were delivered to the stent implantation site with an infiltrator delivery system (Interventional
Technologies, San Diego, California). Animals were euthanized at 2, 6 and 18 h after
interventions, and excised vessels were analyzed for c-myc expression by Western blot. In
long-term experiments, either saline or a dose of 1, 5 or 10 mg of Resten-NG was delivered
in the same fashion, and animals were euthanized at 28 days after the intervention.
RESULTS Western blot analysis demonstrated inhibition of c-myc expression and was dose dependent.
Morphometry showed that the intimal area was 3.88  1.04 mm2 in the control. There was
statistically significant reduction of intimal areas in the 5 and 10 mg groups (2.01  0.66 and
1.95  0.91, respectively, p  0.001) but no significant reduction in the 1 mg group (2.81 
0.56, p  0.5) in comparison with control.
CONCLUSIONS This study demonstrated that intramural delivery of advanced c-myc neutrally charged
antisense morpholino compound completely inhibits c-myc expression and dramatically
reduces neointimal formation in a dose dependent fashion in a porcine coronary stent
restenosis model, while allowing for complete vascular healing. (J Am Coll Cardiol 2002;
39:1686–91) © 2002 by the American College of Cardiology Foundation
A potential application of molecular therapy with antisense
oligonucleotides is the prevention or treatment of restenosis
after coronary interventions (1,2). Balloon and/or stent
injuries result in neointimal hyperplasia that lead to recur-
rent narrowing of the lumen within months after interven-
tion (3). Alternatively, direct interference of the critical
steps in the smooth muscle cell growth cycle has been
attempted, using antisense oligonucleotides in animal mod-
els (4–7). Inhibition of several cellular proto-oncogenes
have been shown to inhibit smooth muscle cell proliferation
in vitro and to reduce neointimal thickening in vivo (7–12).
The clinical use of antisense technology, however, remained
limited due to a relative lack of specificity, slow uptake
across the cell membrane and rapid intracellular degradation
of the oligonucleotide (13). Therefore, one study in humans
using local delivery c-myc antisense has yielded a negative
result (14).
Recent studies have introduced phosphorodiamidate
morpholino oligomers (PMO), which represent an unusual
DNA chemistry with a six-membered morpholino ring
instead of a deoxyribose sugar. In addition, the charged
phosphodiester and uncharged phosphorothioate linkage
replaces internucleotide linkage. The lack of internucleoside
charge allows the PMO to avoid the tendency of the more
common phosphorothioate analogs to produce nonspecific
effects through binding of cellular and extracellular proteins
(15–17). The PMO are resistant to the nucleases found in
serum (18) and exhibit a high degree of specificity and
efficacy in both in vitro and cell free translation studies
(19–22).
It was also demonstrated that endoluminal delivery of
c-myc neutrally charged antisense oligonucleotide with a
transport catheter reduces neointimal formation and posi-
tively affects the vascular remodeling in the rabbit balloon
injury model (23).
The objective of the present study was: 1) to evaluate the
effect of local antisense therapy using advanced PMO with
c-myc antisense oligonucleotides (Resten-NG) on c-myc
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expression after stent implantation and 2) to determine the
long-term influence of local antisense therapy on neointimal
hyperplasia after stenting in a pig coronary model.
METHODS
Oligonucleotide synthesis and purification. Phosphoro-
diamidate morpholine oligomers were synthesized at AVI
BioPharma as described previously (24). The Resten-NG
sequence is complementary to the c-myc messenger ribo-
nucleic acid at the translation initiation start site, 5 ACG-
TTGAGGGGCATCGTCGC-3, and the control se-
quence employed in cell culture studies contains the
sequence 5-ACTGTGAGGGCGATCGCTGC-3. The
PMOs were purified by ion exchange chromatography.
Purity was 90% full length 20-mer as determined by
reverse phase HPLC (high performance liquid chromatog-
raphy) MALADI TOF mass spectroscopy.
Western blot analysis. Western blot analysis involved a
8.7 g protein sample of HeLA cell lysate that was loaded
onto a polyacrylamide gel, a 4% stacking gel and an 8%
running gel at 100 V for 2 h. The gel was then electroblot-
ted onto immobilon P membrane from Millipore (Bedford,
Massachusetts). Actin served as an internal standard probed
with a mouse monoclonal primary antibody, AC40, from
Sigma Chemical Co. (St. Louis, Missouri). The c-myc
expression was measured with a mouse monoclonal primary
antibody, C-33, from Santa Cruz Biotechnology (Santa
Cruz, California). Both actin and c-myc antibodies were
identified with secondary goat anti-mouse IgG antibodies
conjugated with horse radish peroxidase from Santa Cruz
Biotechnology. The immunoblot bands were visualized by
chemiluminescence with Amersham Pharmacia ECI detec-
tion reagents (Piscataway, New Jersey).
Animals and experimental protocol. Animals used in this
study received humane care in compliance with the “Prin-
ciples of Laboratory Animal Care,” formulated by the
National Society for Medical Research, and the “Guide for
the Care and Use of Laboratory Animals,” prepared by the
National Academy of Sciences and published by the Na-
tional Institutes of Health (NIH publication #85-23, re-
vised 1985).
Eighteen female or male juvenile pigs fed on a standard
natural grain diet (25 to 30 kg) were sedated with a
combination of ketamine (20 mg/kg) and xylazine (2 mg/
kg) by intramuscular injection. The animals were given
pentobarbital (10 to 30 mg/kg IV) and were subsequently
intubated and ventilated with oxygen (2 l/min) and isoflu-
rane 1% (1.5 l/min) using a respirator. Adequate anesthesia
was confirmed by the absence of a limb withdrawal reflex.
Limb-lead electrocardiography and blood pressure (Honey-
well E for M) were monitored throughout the procedure.
After placement of an 8F-introducer sheath in the right
carotid artery by surgical cutdown, each animal received
heparin (150 U/kg). Under fluoroscopic guidance, an 8F
guiding catheter was positioned in the left or right coronary
ostium. Coronary angiography was performed after intra-
coronary nitroglycerin (200 g) administration and re-
corded on cine film (Phillips Cardiodiagnost, Shelton,
Connecticut).
Antisense delivery. Antisense drug delivery was performed
at the proximal and/or mid segments of the left anterior
descending, left circumflex or right coronary arteries via the
Infiltrator Balloon Catheter (IBC) 3.0 to 3.5 mm in
diameter and 15 mm in length (Interventional Technolo-
gies, San Diego, California). The IBC was inflated to 2 atms
at the target site, and 0.4 ml of saline (control group) or 0.4 ml
of antisense drug of different doses (from 0.5 to 10 mg) were
infused intramurally via drug delivery InjectorPortsTM using
slow pressure hand delivery over approximately 20 s. The
balloon inflation pressure was then increased to 4 atms, and the
IBC was held in place for an additional 30 s. The total time
necessary to deliver infusate was approximately 1 min for each
delivery, and the balloon-to-artery ratio was kept at 1:1.
Coronary stenting was performed at the site of delivery
using V-Flex stents 15 mm length (Cook Inc., Blooming-
ton, Indiana), hand crimped on the balloon and deployed at
high pressure (10 to 14 atms  30 sec). The stents were
mounted on a balloon 3.5 to 4.0 mm in diameter and
20 mm in length. The stent artery ratio was kept between
1:1.1 and 1:1.2. Immediately post procedure, angiograms
were performed to assess vessel patency; the carotid sheath
was removed, the carotid artery was ligated, the skin was
closed, and the animal was allowed to recover. All animals
were pre-treated with aspirin 325 mg and ticlopidine
250 mg bid, from 24 h before the procedure until animals
were euthanized.
C-myc expression after stent implantation and antisense
delivery. To evaluate the impact of antisense delivery on
c-myc expression after stent implantation, five juvenile pigs
weighing 30 to 35 kg underwent oversized multiple stent
implantation (four per animal) in the coronary artery. In
another five animals (four treatment sites per animal), this
was followed by local Resten-NG delivery (0.5, 1, 3 and
5 mg), using the infiltrator catheter. In those animals, two of
the sites were control sites (saline delivery). At either 2 to
6 h, or 18 h, after the procedure, the pigs were euthanized,
and treated tissue was analyzed by western blot for the
expression of c-myc.
Long-term studies: influence on neointimal hyperplasia.
Eight animals were treated in the same fashion. Treatment
sites were assigned at random to either control or treatment
with three different doses of Resten-NG delivery (1, 5 and
10 mg) with an IBC. At four weeks the animals were
Abbreviations and Acronyms
H&E  hematoxylin and eosin
IBC  Infiltrator Balloon Catheter
PMO  phosphorothioate morpholino oligomers
PTCA  percutaneous transluminal coronary angioplasty
SMC  smooth muscle cell
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euthanized. The arteries were perfusion-fixed, and the
injured segments located with the guidance of the coronary
angiograms were dissected free from the heart. After artery
removal, the hearts were sectioned transaxially at 1-cm
intervals, and sections were examined grossly for evidence of
myocardial damage. The stented segments were processed
for plastic embedding, staining and histomorphometric
analysis of arteries (5 to 8 sections per vessel were averaged,
expressed as mean value  SD) by use of published
methods (25). The grading scheme was used (25,26) to
determine the maturity of vascular repair (endotheliali-
zation, intimal fibrin, inflammation, intimal SMC content,
adventitial fibrosis).
Transmission electron microscopy. Endothelial structure
was studied using transmission electron microscopy. Seg-
ments of arteries were fixed in 3% glutaraldehyde for 24 h
and then transferred to sodium cacdylate buffer. Dehydrated
specimens were embedded in Polybed 812 (Polysciences,
Warrington, Pennsylvania), thin-sectioned and stained with
uranyl acetate and lead citrate, and examined with a Philips
301 electron microscope (Eindhoven, The Netherlands).
Statistical evaluation. Data (mean  SD) were analyzed
for overall differences between treatment groups, using
one-way analysis of variance with the Bonferroni correction.
Comparison of the mean values with a p value of0.05 was
considered statistically different. All statistics were per-
formed using SPSS 10.0 for Windows (SPSS, Inc., Chi-
cago, Illinois). The intimal area and injury score were
correlated using linear regression analysis.
RESULTS
Eighteen animals underwent intervention on 72 coronary
arteries. The antisense drug was delivered to segments of
each coronary artery, and coronary stents were implanted
successfully at the sites where the antisense drug was
delivered. All pigs survived to completion of the four-week
study without evidence of myocardial infarction on gross
inspection and also after histological evaluation.
C-myc expression after balloon angioplasty and antisense
delivery. High performance liquid chromatography analy-
sis of vessel tissue for Resten-NG showed dose dependent
delivery of Resten-NG from 0.5 to 5 mg into the injured
segment. Local delivery of Resten-NG into coronary arter-
ies by infiltrator catheter blocked expression of c-myc
induced by stent implantation by western blot analysis of
vessel tissue and was dose-dependent (Fig. 1).
Histological and morphometric analysis. All stents were
well developed within the vessel, resulting in thinning of the
media adjacent to the stent struts. In the rare vessels with
stent protrusion into the adventitia, there was evidence of
perivascular hemorrhage (Fig. 2). No cases of thrombosis of
the treated segment were observed in any of the treatment
groups (Table 1). We observed complete healing with
virtually no toxicity in all treatment groups. Re-
endothelialization was complete in all treatment groups
(Table 1). Transmission electron microscopy of antisense-
treated vessels demonstrated normal appearance of endo-
thelial cells with tight junctions between cells. There was no
significant intimal fibrin in any groups. Inflammation score
as well as adventitial fibrosis was similar in control and
antisense treatment arteries (Table 1). The neointima from
antisense treated arteries with doses of 5 and 10 mg was
smaller in size than the controls. Control arteries exhibited
a substantial neointima consisting mostly of stellate and
spindle-shaped cells in a loose extracellular matrix. In the
antisense treated arteries, the cells of the neointima were
morphologically similar to controls.
The quantitative histomorphometry results of the control
and antisense treated arteries are shown in Table 2. No
significant difference was seen in vessel size between control
and antisense treated groups. These results demonstrate a
statistically significant reduction of intimal area (IA) and IA
normalized to injury score (IS) after treatment with anti-
sense of 5 and 10 mg. There was a strong trend favoring the
Figure 2. Cross-section samples of the control and the three dosage groups
showing area percent stenosis of 69%, 45%, 32% and 25%, respectively
(Metachromatic stain, Original magnification s.09X).
Figure 1. Data from Western blot analysis of porcine coronary arteries for
c-myc and actin protein expression. Two hours following: (1) Stent; (2)
Stent  0.5 mg Resten-NG; (3) Stent  1.0 mg Resten-NG; (4) Stent 
3.0 mg Resten-NG; (5) Stent  5.0 mg Resten-NG.
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1-mg group versus control, and a significantly larger lumen
area with use of antisense treatment with 5 and 10 mg versus
control. The regression analysis between IS and IA dem-
onstrated that the significant decrease in slope between
treated and control groups indicates that local delivery of
antisense results in significantly less intimal growth despite
similar degrees of arterial injury (Fig. 3).
DISCUSSION
Rationale for vascular applications of antisense molecu-
lar therapy. Because of the proliferative component of the
restenotic process, it is not surprising that most of the
attention of antisense technology has focused on the short-
lived regulators of the final common pathway of mitogenic
stimuli, the cell cycle. Inhibition of the production of several
of the mediators of the cell cycle with antisense oligonucle-
otides has been shown to be effective for the prevention of
restenosis in several different animal models of vascular
injury (5–11).
However, the results of a single-center clinical trial
performed in Rotterdam that examined the effectiveness of
an antisense compound directed against c-myc were recently
reported with disappointing results (14). The authors used a
self-expanding stent, which can cause chronic injury to
stented arteries. In these circumstances a single injection of
antisense may not be adequate to reduce a neointimal
response to ongoing injury (vessel stretch). Additionally, the
RNAse H competent nucleotide chemistries, such as the
phosphorothioate used in the Investigation by the Thorax-
center on Antisense DNA Given by Local Delivery and
Assessed by IVUS after Coronary Stenting (ITALICS)
clinical trial, lacks specificity, in part because duplexes as
short as five base pairs in length can be cleaved by RNAse
H (26). Cleavage of the RNA in such short duplexes might
occur at a rate of 1 in every 1,000 bases of RNA sequence or
nearly once in every transcript from every gene. Hence, the
advantages of the PMO chemistry represent fundamental
improvements in the selective inhibition of target gene
mRNA over earlier antisense approaches and, therefore,
worth consideration in the prevention of restenosis.
We choose early onco-gene c-myc as a target because of
its multiple role in development of neointimal hyperplasia.
It was previously demonstrated that, along with the pro-
found antiproliferative and antimigrative effects, c-myc
antisense has significant anti-inflammatory properties, and
most importantly, it also inhibits matrix production (23).
Indeed, we recently evaluated the long-term impact of
local delivery of c-myc neutrally charged antisense oligonu-
cleotides on intimal hyperplasia after percutaneous translu-
minal coronary angioplasty in a rabbit model (23). Mor-
phometry at eight weeks showed significant inhibition of
intimal hyperplasia.
Comparison with other antirestenotic strategies. Because
of its low toxicity and local application, intramural delivery
of antisense may be theoretically more attractive than other
methods of suppressing excessive intimal response after
mechanical injury (radiation, etc.).
A large number of experimental and clinical studies have
demonstrated that endoluminal-ionizing radiation reduces
cellular proliferation and restenosis (27). However, edge
effect, late thrombosis, and increased risk of myocardial
infarction represent significant limitations of this therapeu-
tic modality (27,28).
Most recently, local antiproliferative strategies, including
pharmacological stent coatings (actinomycin-D, paclitaxel,
rapamycin, etc.), have demonstrated inhibition of smooth
muscle cell proliferation in vitro, have reduced neointimal
thickening in animal models of restenosis (26,29,30) and
have produced promising results in a pilot human study
Table 1. Antisense Histopathologic Findings
Tissue Event
Antisense Dose
0 g 1 g 5 g 10 g
Endothelialization
score
3 3 3 3
Inflammation score 0.47  0.49 0.29  0.25 0.39  0.47 0.25  0.17
Intimal vascularity 0.47  0.45 0.08  0.13 0.33  0.60 0.13  0.32
Medial wall tissue
necrosis
ND ND ND ND
Intimal fibrin 0.53  0.39 0.58  0.30 0.33  0.25 0.50  0.35
Neointimal SMC 2.44  0.37 2.33  0.21 2.81  0.33 2.78  0.30
Adventitial fibrosis 0.40  0.36 0.48  0.2 0.58  0.64 0.40  0.8
Thrombosis ND ND ND ND
Data are presented as the mean value  SD. (Grading scheme, see Methods).
ND  not detected; SMC  smooth muscle cells.
Table 2. Histomorphometric Results in Porcine Coronary Arteries 28 Days After Local Delivery
of Antisense and Stent Implantation
Control
(n  6)
1 mg
(n  8)
5 mg
(n  9)
10 mg
(n  7) p Value*
Vessel area (mm2) 9.29  1.24 9.54  1.79 9.02  1.54 9.72  1.98 0.262
Stent strut area (mm2) 7.14  1.04 7.56  1.48 6.86  1.11 7.63  1.59 0.585
Luminal area (mm2) 3.26  1.57 4.76  1.85 4.91  1.36 5.62  1.40† 0.062
IA (mm2) 3.88  1.04 2.81  0.56 2.01  0.66† 1.95  0.91† 0.001
Medial area (mm2) 2.05  0.31 1.97  0.42 2.04  0.42 2.16  0.49 0.459
IS 0.95  0.46 0.91  0.46 0.90  0.34 0.94  0.44 0.546
IA/IS 4.08  0.76 3.09  0.50 2.17  0.67† 2.13  0.55† 0.001
*By analysis of variance (ANOVA). †p  0.05 vs. control (ANOVA post-test with Bonferroni correction). Data are presented
as the mean value  SD.
IA  intima area; IS  injury score.
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(31). However high local toxicity may alter the endotheli-
alization process after stent implantation and may cause late
complications.
By contrast with other chemotherapeutics (paclitaxel,
actinomycin-D), Resten-NG inhibits cell cycle in the G-1.
Compounds that inhibit the cell cycle in the early phase are
often less toxic. Therefore, Resten-NG as well as Rapamy-
cin fit this description. Additionally, antisense can inhibit
the cell cycle at a number of points, so it may be effective
regardless of the stage of cell growth at which the drug is
applied.
This study also showed that re-endothelialization was
completed at 4 weeks in all treatment groups. Vascular
healing, inflammation, fibrin deposition and adventitial
fibrosis was similar to control arteries.
Study limitations. The major limitation of this study is
that relevance of different animal models of neointimal
hyperplasia to human restenotic process is not yet well
established. The long-term effect of local delivery of anti-
sense is unknown. However, observed complete vascular
healing at 28 days after antisense delivery and stent implan-
tation may suggest that possible late complications, includ-
ing late thrombosis, are not likely to take place at three or six
months in this animal model or in clinical circumstances.
CONCLUSIONS
This study demonstrated that intramural delivery of ad-
vanced c-myc neutrally charged antisense morpholino com-
pound inhibits c-myc expression and dramatically reduces
neointimal formation in a dose dependent fashion in a
porcine coronary stent restenosis model while allowing for
complete vascular healing. Clinical trials (AVI-4126) are
underway to further establish the efficacy of this interven-
tion in man.
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Figure 3. Regression analysis between injury score and intimal area. The significant decrease in slope between treated and control groups indicates that local
delivery of antisense results in significantly less intimal growth despite similar degrees of arterial injury. Each data point represents a single treated arterial
segment.
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